JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Safety and Efficacy of Antibacterial Prophylaxis After Craniotomy: A Decision Model Analysis.

World Neurosurgery 2017 September
BACKGROUND: Antibiotic prophylaxis has revolutionized the safety of neurosurgical procedures in the last century. Today, the clinician's drug of choice before surgery often is based on the antibiotic's resistance profile and drug-induced complications.

METHODS: A decision tree model was developed to compare cefazolin (cephalosporin), vancomycin, or their combination on 90-day mortality postcraniotomy. We modeled the infection type (methicillin-sensitive, methicillin-resistant, or other organisms), antibiotic-related complications that could affect mortality (e.g., renal injury), and Clostridium difficile infections. Parameters' values were extracted from published sources. One-way sensitivity analysis was used to examine results' robustness to plausible variations in input parameter values.

RESULTS: The expected value (EV) of 90-day survival was the greatest among patients on cefazolin (EV = 0.9145), followed by patients on vancomycin (EV = 0.8898), and patients on the combination (EV = 0.8886). Cefazolin was the preferred strategy in most one-way sensitivity analyses, except for a few cases in which other options could be preferred based on expected survival. Vancomycin was preferred if kidney injury risk was ≤0.056 conditional on vancomycin intake or ≥12% conditional on cefazolin intake. The combination was preferred if kidney injury conditional risk was ≤0.083 or that for kidney injury-mortality was ≤4.7%. Varying other risks (e.g., postsurgical-site infections (methicillin-resistant Staphylococcus aureus, methicillin-sensitive Staphylococcus aureus, or other); Clostridium difficile infections' risks conditional on each antibiotic) did not change the preferred strategy.

CONCLUSIONS: According to this decision analysis, patients undergoing a craniotomy who had cefazolin as prophylaxis had a slightly greater expected survival compared with other strategies. These results were sensitive to changes in kidney injury development risk and kidney failure-associated death.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app